Accelerated Development of Brain-Computer Interfaces in China
China is accelerating brain-computer interface development, moving from research to commercialization thanks to supportive policies, expanding clinical trials and growing investor interest.
China is experiencing rapid development in the brain-computer interface (BCI) sector, moving from the research phase to commercialization. This progress is fueled by strong government support, an expansion of clinical trials and growing interest from investors.
Government Support and Strategic Roadmap
In 2025, the Ministry of Industry and Information Technology, together with six other government agencies, issued a national roadmap to accelerate the development of BCIs. The plan sets significant technical milestones by 2027, the adoption of common industry standards and the creation of a complete supply chain by 2030, with the aim of building globally competitive BCI companies and supporting specialized small and medium-sized enterprises.
Clinical Trials and Technological Progress
Chinese companies are accelerating clinical trials of BCIs, in some cases outpacing Western competitors. For example, NeuroXess successfully began human trials, enabling a paralyzed patient to control a computer cursor just five days after implantation. This progress is made possible by a mix of government support and investor enthusiasm, which speeds up time-to-market for Chinese BCI technologies.
Investment and Market Growth
The BCI sector in China is attracting significant investment. In February 2025, Shanghai-based BCI startup StairMed Technology raised $48 million (350 million yuan) in a Series B funding round. In addition, BrainCo, a neurotechnology company developing non-invasive BCIs and bionic limbs, filed for a Hong Kong listing after raising $287 million (2 billion yuan) earlier in the year. This investment is fueling market growth, which is expected to exceed $530 million (3.8 billion yuan) in 2025, with projections indicating a market of more than 120 billion yuan by 2040.
Implications for the Technology and Healthcare Sectors
The rapid development of BCIs in China has significant implications for the technology and healthcare sectors. BCIs offer potential applications in areas such as medical rehabilitation, industrial automation and consumer electronics. Moreover, China's coordinated approach, which integrates research, development and commercialization, could position it as a global leader in the BCI sector, challenging companies such as Neuralink in the United States.
Takeaways
- Strategic government support: China has implemented a national roadmap to accelerate BCI development, with clear targets for 2027 and 2030.
- Accelerating clinical trials: Chinese companies are outpacing Western competitors in BCI clinical trials, with significant progress in a short time.
- Growing investment: The BCI sector in China is attracting significant investment, with long-term market growth projections.
- Global implications: The development of BCIs in China could challenge the leadership of companies such as Neuralink, shaping the global landscape of neurotechnology.
- Opportunities for healthcare: BCIs offer potential applications in areas such as medical rehabilitation, industrial automation and consumer electronics, opening new opportunities for the healthcare sector.